When will the COVID-19 pandemic end?

December 15, 2021

On November 26, 2021, WHO reached deeper into the Greek alphabet to declare Omicron a new SARS-CoV-2 variant of concern. 1 1. “Update on Omicron,” WHO, November 28, 2021. The world’s reaction has been an unpleasant mixture of dread, fatigue, and déjà vu. Almost two years into a pandemic that has claimed more than five million lives and affected billions more, people everywhere are finding it hard to summon the energy for another chapter in the story. 2 2. Charlie Giattino et al., “Excess mortality during the coronavirus pandemic (COVID-19),” Our World in Data, December 7, 2021.

Endemicity remains the endpoint. But at the time of writing, the Omicron variant is rewriting the timetable. Whether because Omicron is more infectious or has greater ability to evade the immune system, or both, it quickly became the dominant variant in South Africa. 3 3. “Genomic epidemiology of novel coronavirus – Africa-focused subsampling,” Nextstrain, December 11, 2021. Data so far are mixed on the severity of the disease it causes: some early findings have pointed toward a mild clinical course, while other evidence has suggested that Omicron may lead to more frequent hospitalization in children than other variants do. 4 4. “Implications of the further emergence and spread of the SARS CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA – first update,” European Centre for Disease Prevention and Control (ECDC), December 2, 2021; Loni Prinsloo, “Toddlers make up 10% of hospital cases in Omicron epicenter,” Bloomberg, November 29, 2021. We have written previously about the transition to managing COVID-19 as an endemic disease and noted that a new variant was one of the greatest risks to timelines.

See more: Covid 19 end date

This article presents a new analysis of a range of scenarios based on the infectiousness, immune evasion, and severity of disease caused by the Omicron variant. Based on the evidence to date, we have posited a base-case scenario in which Omicron is about 25 percent more infectious, evades prior immunity to a greater degree (25 percent), and causes less severe disease, again by about 25 percent, all relative to Delta. 5 5. Based on analysis of all sources cited. Others have also advanced this view; for an example, see Grady McGregor, “Evidence mounts that Omicron is more infectious, less severe than Delta—but Fauci, other experts warn against premature optimism,” Fortune, December 6, 2021. Our analysis suggests that in the United States, this combination of characteristics would lead to Omicron replacing Delta as the dominant variant in the next few months and to a higher peak burden of disease than the country saw in the second half of 2021 (but likely below the peak reached in the winter of 2020-21).

This base-case scenario has the potential to place a severe strain on healthcare systems. The optimistic scenario would see a peak of disease burden close to that seen over the past six months, while the pessimistic would see a very significantly higher burden of disease than in the past six months. Note that in every scenario, our analysis indicates that hospitalizations will likely be higher in the next six months than they were in the past six months.

In any scenario for the future of the COVID-19 pandemic, much depends on the ways in which societies respond. Three levers are likely to be especially important, starting with the extent to which countries can effectively scale and make available new oral therapeutics with the potential to reduce the chance of progression to severe disease, and which are unlikely to be blunted by Omicron. Second, evidence is accumulating that booster doses are especially important for protecting against the Omicron variant; accelerating their rollout will help protect populations. And third, given public fatigue and the lessons of the past two years, finding the right combination of public-health measures will be critical.

The Omicron variant

Three main factors determine the real-world impact of any new SARS-CoV-2 variant: the extent to which it can evade the immunity developed by those who have been vaccinated or previously infected by other variants, its inherent infectiousness (often expressed as a higher basic reproduction number, or R0), and the severity of disease caused. 6 6. Ewen Callaway and Heidi Ledford, “How bad is Omicron? What scientists know so far,” Nature, December 2, 2021. The first two factors combine to drive the number of cases, while the third determines the number of severe cases and deaths. For example, the Delta variant, which remains dominant in most of the world, was significantly more transmissible than previously circulating variants were, showed limited incremental evasion of immunity, and caused moderately more severe disease relative to other variants. 7 7. “Delta variant: What we know about the science,” US Centers for Disease Control and Prevention, August 26, 2021.

Early data paint a mixed picture of Omicron’s evasion of vaccine-induced immunity. The UK Health Security Agency recently summed up its view: “Early estimates of vaccine effectiveness (VE) against symptomatic infection find a significantly lower VE [against] Omicron infection compared to Delta infection. Nevertheless, a moderate to high [VE] of 70 to 75% is seen in the early period after a booster dose.” 8 8. “SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 31,” UK Health Security Agency, December 13, 2021.

There is still much more to learn—sample sizes in the new studies were small, antibody titers are an imperfect metric of immune protection, and major manufacturers are yet to release similar information. The response to Omicron may include both accelerating the rollout of booster doses of existing vaccines and developing new formulations better targeted to this variant. Companies have indicated that modified or new vaccines could be available in a few months, though the scale and global availability are unclear. 9 9. “Pfizer and BioNTech provide update,” December 8, 2021; Khristopher J. Brooks, “CEOs and scientists on whether existing vaccines will work against Omicron,” CBS News, December 8, 2021.

Regarding evasion of natural immunity, a preprint article from South Africa suggests a significantly higher chance of reinfection by Omicron relative to Delta or Beta. 10 10. Juliet R. C. Pulliam et al., “Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa,” medRxiv, December 2, 2021. Both the pace of case growth and the rapidly increasing share of Omicron among samples sequenced suggest that, through a combination of greater infectiousness and immune evasion, Omicron is spreading very quickly. 11 11. Sarah Zhang, “Omicron’s explosive growth is a warning sign,” Atlantic, December 8, 2021. If the experience of South Africa were to be repeated elsewhere, we could see a continued rapid increase in the number of COVID-19 cases as Omicron is established.

The question of disease severity is more complicated. Several clinicians in South Africa have noted the apparently mild presentation of Omicron cases. 12 12. Fareed Abdullah, “Tshwane district Omicron variant patient profile – early features,” South African Medical Research Council, December 8, 2021. Further, the European Centre for Disease Prevention and Control (ECDC) noted on December 12, 2021, that 776 cases were within its remit and “all cases for which there is available information on severity were either asymptomatic or mild. There have been no Omicron-related deaths reported thus far.” 13 13. “Epidemiological update: Omicron variant of concern (VOC) – data as of 12 December 2021 (12.00),” ECDC, December 12, 2021. On the other hand, ECDC also notes that it is too early to draw definitive conclusions on disease severity. The United Kingdom reported its first Omicron-related death on December 13, 2021, and some reports from South Africa suggest a potentially higher rate of hospitalization among young children than seen in previous waves of COVID-19. 14 14. Becky Morton and Doug Faulkner, “Covid: First UK death recorded with Omicron variant,” BBC News, December 13, 2021; Mahsa Saeidi, “South Africa reports rise of omicron hospitalization of kids under 5, initial data shows,” WFLA, December 6, 2021.

Each of these observed trends may change as sample sizes increase, confounding factors are considered, and the clinical course of disease plays out over time. The answers, when they arrive, will have important consequences for the months ahead. Given the uncertainty, we have built a set of scenarios describing potential outcomes measured by hospitalization rate. They are indexed on the recent Delta wave and show whether various potential combinations of infectiousness, immune evasion, and clinical severity are likely to lead to a higher or lower rate of COVID-19-related hospitalization.

The results of these scenarios for the United States are shown in Exhibit 1. Each of the three variables is an important driver of the outcomes. Evidence so far suggests that the Omicron variant, relative to Delta, is likely to be more infectious, show more immune evasion, and be less severe, on average. In the base case (25 percent more infectious; 25 percent greater immune evasion; 25 percent less severe disease), the COVID-19-related hospitalization rate in the United States could peak significantly higher in the next six months than in the past six. In the pessimistic scenarios, the peak number of hospitalizations for COVID-19 could be much higher in the next six months than in the past six months, whereas in the optimistic scenario, the number would be higher but similar to that seen in the second half of 2021, as waning immunity causes ongoing disease from a combination of the Delta and Omicron variants.

Exhibit 1 We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

The analysis is quite sensitive to public-health interventions and behaviors. Exhibit 1 assumes a US public-health response similar to that seen during the Delta wave. Exhibit 2 shows potential outcomes if more stringent public-health measures were to be employed in the United States; this could lead to a disease burden that is similar to or only moderately worse than seen in the past six months, depending on the characteristics of the virus. The exhibit also shows how much more stringent those measures would need to be to potentially prevent the disease burden from exceeding the burden of Delta. Our analysis accounts for waning immunity and suggests that even if Omicron were to have no impact, the next six months of Delta-driven disease in the United States could be about as severe as the past six months were.

In the context of Omicron’s arrival and impending spread, three factors come to the forefront: the potential impact of new therapeutics in reducing hospitalizations and death, the criticality of boosters in the context of waning immunity, and clarity and consensus in public-health measures.

Oral therapeutics

The clinical management of COVID-19 has come a long way since the early days of the pandemic. The availability of effective monoclonal antibodies, dexamethasone, and other treatments and the use of nonpharmacological interventions, such as “proning,” have meaningfully increased the chances of survival for those with access to high-quality healthcare. 15 15. Stephan Ehrmann et al., “Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: A randomised, controlled, multinational, open-label meta-trial,” Lancet: Respiratory Medicine, December 1, 2021, Volume 9, Number 12; Peter Horby et al., “Dexamethasone in hospitalized patients with COVID-19,” The New England Journal of Medicine, February 25, 2021. Nevertheless, recent results from Merck-Ridgeback Biotherapeutics and Pfizer on their oral drugs molnupiravir and PAXLOVID, respectively (two antivirals, with different mechanisms of action 16 16. “Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19,” Merck, November 26, 2021; “Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase 2/3 EPIC-HR study,” Pfizer, November 5, 2021. ) represent a material advancement and increase the chance that the impact of the Omicron variant can be controlled. In its final study, Pfizer reported that PAXLOVID reduced risk of hospitalization or death by about 89 percent for high-risk patients and about 70 percent for standard-risk patients. 17 17. “Pfizer announces additional Phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death,” December 14, 2021.

Oral therapeutics that significantly reduce the chance of progression to severe disease after symptom onset may enable a higher fraction of cases to be managed as outpatients. Such therapies are also easier to administer in lower-resourced regions than injected or infused treatments are. Further, manufacturing small molecules rapidly is faster than the process for monoclonal antibodies. The initial evidence indicates that the efficacy of these therapies is unlikely to be reduced by the mutations present in the Omicron variant. 18 18. Jason Gale and John Lauerman, “How does Omicron challenge the treatments for Covid?,” Bloomberg, December 9, 2021.

A number of questions and caveats remain. Data are not yet available on the drugs’ efficacy in vaccinated individuals. The drugs are more likely to be effective if taken within five days of symptom onset, 19 19. “Merck and Ridgeback Biotherapeutics provide update,” November 26, 2021; “Pfizer’s novel COVID-19 oral antiviral treatment candidate,” November 5, 2021. requiring an efficient pathway from diagnosis to prescription and distribution. And some data inconsistencies have emerged—for example, it is unclear why molnupiravir’s efficacy in an interim analysis dropped in the final readout. 20 20. “Merck and Ridgeback Biotherapeutics provide update,” November 26, 2021.

Other questions relate to the impact of the new therapeutics in blunting an Omicron-driven wave of disease. Can healthcare systems diagnose COVID-19 and distribute therapeutics fast enough for them to be effective? Will oral therapeutics be available quickly enough to blunt a potential Omicron surge in December 2021 and January 2022? How will drug-drug interactions with ritonavir be managed for PAXLOVID use? Can mutagenicity concerns in pregnant women for molnupiravir be managed to ensure patient safety while maximizing effective use of the drug? What role will antibody treatments play?

Waning immunity and boosters

The decline in the efficacy of COVID-19 vaccines over time and the benefits of booster doses have become much better understood over the past three months. While an initial course of all WHO-approved vaccines continues to provide strong protection against severe illness and death, the rate of breakthrough cases increases meaningfully as time passes, indicating that protection declines with time. For example, a July 2021 study of the Pfizer-BioNTech vaccine in Israel showed that in every age group studied, those who had been vaccinated by January 2021 were more likely to experience breakthrough infection than those who completed their initial course of vaccination two months later were. 21 21. Yair Goldberg et al., “Waning immunity after the BNT162b2 vaccine in Israel,” New England Journal of Medicine, December 9, 2021, Volume 385. This general point appears to be especially true for the Omicron variant. 22 22. “Pfizer and BioNTech provide update,” December 8, 2021.

Evidence has also accumulated steadily about the benefit of booster doses, leading more countries to expand and accelerate their rollout. 23 23. “Factbox: Countries weigh need for booster COVID-19 shots,” Reuters, December 8, 2021. On October 21, 2021, Pfizer-BioNTech announced results from a randomized controlled trial of third doses of its COVID-19 vaccine; protection was restored to the levels seen in earlier trials after the second dose. 24 24. “Pfizer and BioNTech announce Phase 3 trial data showing high efficacy of a booster dose of their COVID-19 vaccine,” Pfizer, October 21, 2021. More recent data, as previously described, highlight the benefits of booster doses in protecting against the Omicron variant.

WHO and others have raised important concerns about the appropriateness of high-income countries offering booster doses of COVID-19 vaccines while so many in the world have not received initial vaccination, but the benefits of a booster dose to an individual patient are increasingly clear. 25 25. “COVID-19 virtual press conference: 8 December 2021,” WHO, December 8, 2021. The ongoing Delta-driven wave of cases in Europe has led a number of countries to accelerate their booster-dose rollout, with some discussing the timing of potential additional doses. 26 26. Alisa Odenheimer, “Israel is preparing for possible fourth Covid vaccine dose,” Bloomberg, September 12, 2021.

As countries transition over time to managing COVID-19 as an endemic disease, the world may reach a long-term state of disease prevention similar to that seen with the flu, with annual or twice yearly booster doses. In the short term, an accelerated rollout of booster doses of COVID-19 vaccines is likely to be one of the best protections against an Omicron-fueled wave of the disease.

Public-health measures

Even before the emergence of Omicron, the past four months have seen the continued evolution of the public response to COVID-19. Debates have continued about the role of vaccine mandates, the use of vaccine passports, testing requirements, masks and mask mandates, and restrictions on gatherings. Societies are trying to find a new consensus through this transition, with some maintaining minimal public-health restrictions in the face of rising case counts and others reinstating more stringent measures. The emergence of Omicron led to tighter rules around travel in many countries, with some, such as England, also restricting domestic travel. 27 27. “Prime Minister confirms move to plan B in England,” United Kingdom, December 8, 2021. Achieving some degree of consensus on public-health measures will likely be an important step toward controlling an Omicron-driven wave of disease.

Omicron is a sobering reminder that SARS-CoV-2 has the advantage of rapid mutation and can produce new variants faster than anyone would like. We hope that this article offers a starting point to interpret the potential spread and severity of the disease it produces and the ways in which new therapeutics, booster doses of vaccines, and public-health measures will be important in limiting its impact.

View more: Post-COVID Conditions: Information for Healthcare Providers

About the authors

Sarun Charumilind is a partner in McKinsey’s Philadelphia office, Matt Craven is a partner in the Bay Area office, Jessica Lamb is a partner in the New Jersey office, Adam Sabow is a senior partner in the Chicago office, Shubham Singhal is a senior partner in the Detroit office, and Matt Wilson is a senior partner in the New York office.

The authors wish to thank Alizeh Hasham Gangji, Giulio Morina, Konstantinos Tsakalis, and Aurora Xu for their contributions to this article.

This article was edited by Mark Staples, an executive editor in the New York office.

August 23, 2021

This article updates our perspectives on when the coronavirus pandemic will end to reflect the latest information on vaccine rollout, variants of concern, and disease progression. Among high-income countries, cases caused by the Delta variant reversed the transition toward normalcy first in the United Kingdom, during June and July of 2021, and subsequently in the United States and elsewhere. Our own analysis supports the view of others that the Delta variant has effectively moved overall herd immunity out of reach in most countries for the time being. The United Kingdom’s experience nevertheless suggests that once a country has weathered a wave of Delta-driven cases, it may be able to resume the transition toward normalcy. Beyond that, a more realistic epidemiological endpoint might arrive not when herd immunity is achieved but when COVID-19 can be managed as an endemic disease. The biggest overall risk would likely then be the emergence of a significant new variant.

Since the March installment in this series, many countries, including the United States, Canada, and those in Western Europe, experienced a measure of relief from the COVID-19 pandemic 28 28. “COVID data tracker weekly review,” Centers for Disease Control and Prevention, last accessed August 15, 2021, daypg.com; COVID-19 daily epidemiology update, Government of Canada, updated August 18, 2021, daypg.com; Colleen Barry, Frank Jordans, and Nicole Winfield, “In time for summer, Europe sees dramatic fall in virus cases,” Associated Press, May 29, 2021, daypg.com. when some locales embarked on the second-quarter transition toward normalcy that we previously discussed. 29 29. See our earlier perspectives, below, for definitions of normalcy and herd immunity. When we refer to herd-immunity timelines for a country, we mean the point at which the entire nation or a significant portion reaches herd immunity. This progress was enabled by rapid vaccine rollout, with most Western European countries and Canada overcoming their slower starts during the first quarter of 2021 and passing the United States in the share of the population that is fully immunized. 30 30. “Tracking coronavirus vaccinations around the world,” New York Times, last accessed August 15, 2021, daypg.com. However, even that share has been too small for them to achieve herd immunity, because of the emergence of the more transmissible and more lethal Delta variant 31 31. Sarah Zhang, “What if we never reach herd immunity?,” Atlantic, February 9, 2021, daypg.com. and the persistence of vaccine hesitancy. 32 32. Jenny Cordina, Eric Levin, and George Stein, “COVID-19 Consumer Healthcare Insights: What 2021 may hold,” June 24, 2021, daypg.com.

Among high-income countries, cases caused by the Delta variant reversed the transition toward normalcy first in the United Kingdom, where a summertime surge of cases led authorities to delay lifting public-health restrictions, and more recently in the United States and elsewhere. The Delta variant increases the short-term burden of disease, causing more cases, hospitalizations, and deaths. 33 33. “Delta variant: What we know about the science,” Centers for Disease Control and Prevention, August 6, 2021, daypg.com; Yasmeen Abutaleb, Joel Achenbach, and Carolyn Y. Johnson, “‘The war has changed’: Internal CDC document urges new messaging, warns delta infections likely more severe,” Washington Post, July 29, 2021, daypg.com; Apoorva Mandavilli, “CDC internal report calls Delta variant as contagious as chickenpox,” New York Times, July 30, 2021, daypg.com; Michaeleen Doucleff, “The Delta variant isn’t as contagious as chickenpox. But it’s still highly contagious,” NPR, August 11, 2021, daypg.com. Delta’s high transmissibility also makes herd immunity harder to achieve: a larger fraction of a given population must be immune to keep Delta from spreading within that population (see sidebar, “Understanding the Delta variant”). Our own analysis supports the view of others that the Delta variant has effectively moved herd immunity out of reach in most countries for now, 34 34. Christie Aschwanden, “Five reasons why COVID herd immunity is probably impossible,” Nature, March 18, 2021, daypg.com. although some regions may come close to it.

While the vaccines used in Western countries remain highly effective at preventing severe disease due to COVID-19, recent data from Israel, the United Kingdom, and the United States have raised new questions about the ability of these vaccines to prevent infection from the Delta variant. 35 35. Arjun Puranik et al., “Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence,” medRxiv, August 8, 2021, daypg.com; Alistair Smout, “English study finds 50-60% reduced risk of COVID for double-vaccinated,” Reuters, August 3, 2021, daypg.com; Berkeley Lovelace Jr., “Israel says Pfizer Covid vaccine is just 39% effective as delta spreads, but still prevents severe illness,” CNBC, July 23, 2021, daypg.com. Serial blood tests suggest that immunity may wane relatively quickly. This has prompted some high-income countries to start offering booster doses to high-risk populations or planning for their rollout. 36 36. Kate Brady and Reis Thebault, “Europe to give covid booster shots as ‘half the world is still starving’ for vaccines,” Washington Post, August 4, 2021, daypg.com; Sharon LaFraniere, “U.S. to advise boosters for most Americans 8 months after vaccination,” New York Times, August 16, 2021, daypg.com. Data from the US Centers for Disease Control and Prevention also suggest that vaccinated people who become infected with the Delta variant may transmit it efficiently. 37 37. “Delta variant,” August 6, 2021; “‘The war has changed’: Internal CDC document,” July 29, 2021; “CDC internal report,” July 30, 2021; “The Delta variant isn’t as contagious,” August 11, 2021.

These events and findings have raised new questions about when the pandemic will end. The United Kingdom’s experience nevertheless suggests that once a country has weathered a Delta-driven wave of cases, it may be able to relax public-health measures and resume the transition toward normalcy. 38 38. Sarah Zhang, “Watch the U.K. to understand Delta,” Atlantic, August 3, 2021, daypg.com. Beyond that, a more realistic epidemiological endpoint might arrive not when herd immunity is achieved but when countries are able to control the burden of COVID-19 enough that it can be managed as an endemic disease. The biggest risk to a country’s ability to do this would likely then be the emergence of a new variant that is more transmissible, more liable to cause hospitalizations and deaths, or more capable of infecting people who have been vaccinated.

Raising vaccination rates will be essential to achieving a transition toward normalcy. Vaccine hesitancy, however, has proven to be a persistent challenge, both to preventing the spread of the Delta variant and to reaching herd immunity. 39 39. “COVID-19 Consumer Healthcare Insights,” June 2021. The US Food and Drug Administration has now fully approved Pfizer’s COVID-19 vaccine, and other full approvals may follow soon, which could help increase vaccination rates. 40 40. “FDA approves first COVID-19 vaccine,” US Food and Drug Administration news release, August 23, 2021, daypg.com. Vaccines are also likely to be made available to children in the coming months, 41 41. Samantha Artiga, Jennifer Kates, Kendal Orgera, and Jennifer Tolbert, “The next stage of COVID-19 vaccine roll-out in United States: Children under 12,” Kaiser Family Foundation, July 30, 2021, daypg.com. making it possible to protect a group that comprises a significant share of the population in some countries.

In this article, we review developments since our March update, offer a perspective on the situation and evidence as of this writing, and present our scenario-based analysis of when a transition toward normalcy could occur.

Even without herd immunity, a transition toward normalcy is possible

We have written previously about two endpoints for the COVID-19 pandemic: a transition toward normalcy, and herd immunity. The transition would gradually normalize aspects of social and economic life, with some public-health measures remaining in effect as people gradually resume prepandemic activities. Many high-income countries did begin such a transition toward normalcy during the second quarter of this year, only to be hit with a new wave of cases caused by the Delta variant and exacerbated by vaccine hesitancy.

Indeed, our scenario analysis suggests that the United States, Canada, and many European countries would likely have reached herd immunity by now if they had faced only the ancestral SARS-CoV-2 virus and if a high percentage of those eligible to receive the vaccine had chosen to take it. But as the more infectious Delta variant becomes more prevalent within a population, more people within that population must be vaccinated before herd immunity can be achieved (Exhibit 1).

Exhibit 1 We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

Vaccine hesitancy makes it all the more difficult to reach the population-wide vaccination level rates that confer herd immunity. Researchers are learning more about differences among individuals’ attitudes, which include both “cautious” and “unlikely to be vaccinated.” 42 42. “COVID-19 Consumer Healthcare Insights,” June 2021. Meanwhile, social tolerance for vaccination incentives and mandates appears to be growing, with more European locations adopting vaccination passes 43 43. EU Digital COVID Certificate, European Commission, accessed August 15, 2021, daypg.com; “Covid passports: How do they work around the world?,” BBC News, July 26, 2021, daypg.com. and more large employers in the United States implementing vaccine mandates. 44 44. Leslie Josephs and Robert Towey, “Covid vaccine mandates sweep across corporate America as delta variant spurs action,” CNBC, August 9, 2021, daypg.com; Alexis Benveniste, “From offices to restaurants, companies are requiring proof of vaccination,” CNN, August 4, 2021, daypg.com.

While it now appears unlikely that large countries will reach overall herd immunity (though some areas might), developments in the United Kingdom during the past few months may help illustrate the prospects for Western countries to transition back toward normalcy. 45 45. “Watch the U.K. to understand Delta,” August 2021; Grady McGregor, Sophie Mellor, and Biman Mukherji, “Delta waves in India and the U.K. have already receded. Could the same happen in the U.S.?,” Fortune, August 3, 2021, daypg.com. Having suffered a wave of cases caused by the Delta variant during June and the first few weeks of July, the country delayed plans to ease many public-health restrictions and eventually did so on July 19, though expansive testing and genomic surveillance remain in place. UK case counts may fluctuate and targeted public-health measures may be reinstated, but our scenario analysis suggests that the country’s renewed transition toward normalcy is likely to continue unless a significant new variant emerges.

The United States, Canada, and much of the European Union are now in the throes of a Delta-driven wave of cases. 46 46. “COVID data tracker weekly review,” accessed August 15, 2021; COVID-19 daily epidemiology update, August 18, 2021; “SARS-COV-2 Delta variant now dominant in much of the European Region and efforts must be reinforced to prevent transmission, warn WHO/Europe and ECDC,” European Centre for Disease Control and Prevention, July 23, 2021, daypg.com; Ceylan Yeginsu, “The new reality of a European trip: ‘Things are going to change,’” New York Times, July 30, 2021, daypg.com. While each country’s situation is different, most have again enacted public-health restrictions, thus reversing their transitions toward normalcy. The trajectory of the epidemic remains uncertain, but the United Kingdom’s experience and estimates of total immunity suggest that many of these countries are likely to see new cases peak late in the third quarter or early in the fourth quarter of 2021. As cases decline, our analysis suggests that the United States, Canada, and the European Union could restart the transition toward normalcy as early as the fourth quarter of 2021, provided that the vaccines used in these countries continue to be effective at preventing severe cases of COVID-19. Allowing for the risk of another new variant and the compound societal risk of a high burden of influenza, respiratory syncytial virus, and other winter respiratory diseases, the question for these countries will be whether they manage to arrive at a different epidemiological endpoint, as we discuss next.

Endemic COVID-19 may be a more realistic endpoint than herd immunity

We have previously written about herd immunity as a likely epidemiological endpoint for some countries, but the Delta variant has put this out of reach in the short term. Instead, it is most likely as of now that countries will reach an alternative epidemiological endpoint, where COVID-19 becomes endemic and societies decide—much as they have with respect to influenza and other diseases—that the ongoing burden of disease is low enough that COVID-19 can be managed as a constant threat rather than an exceptional one requiring society-defining interventions. One step toward this endpoint could be shifting the focus of public-health efforts from managing case counts to managing severe illnesses and deaths. Singapore’s government has announced that it will make this shift, and more countries may follow its lead. 47 47. Niharika Mandhana, “From pandemic to endemic, Singapore creates model for living with Covid-19,” Wall Street Journal, July 1, 2021, daypg.com.

Other authors have compared the burden of COVID-19 with that of other diseases, such as influenza, as a way to understand when endemicity might occur. 48 48. Alexis Madrigal, “A simple rule of thumb for knowing when the pandemic is over,” Atlantic, February 23, 2021, daypg.com; Stephen M. Kissler et al., “Projecting the transmission dynamics of SARS-C0V-2 through the postpandemic period,” Science, May 22, 2020, Volume 368, Issue 6493, pp. 860-68, daypg.com; William A. Haseltine, “Covid-19 could end up like the flu—or worse,” Forbes, February 11, 2021, daypg.com; Helen Branswell, “How the Covid pandemic ends: Scientists look to the past to see the future,” STAT, May 19, 2021, daypg.com. In the United States, COVID-19 hospitalization and mortality rates in June and July were nearing the ten-year average rates for influenza but have since risen. Today, the burden of disease caused by COVID-19 in vaccinated people in the United States is similar to or lower than the average burden of influenza over the last decade, while the risks from COVID-19 to unvaccinated people are significantly higher (Exhibit 2). This comparison should be qualified, insofar as the burden of COVID-19 is dynamic, currently increasing, and uneven geographically. It nevertheless helps illustrate the relative threat posed by the two diseases.

Countries experiencing a Delta-driven wave of cases may be more likely to begin managing COVID-19 as an endemic disease after cases go into decline. 49 49. “From pandemic to endemic,” July 1, 2021. The United Kingdom appears to be making this shift now (though cases there were increasing as of this writing). For the United States and the European Union, scenario analysis suggests that the shift may begin in the fourth quarter of 2021 and continue into early 2022 (Exhibit 3). As it progresses, countries would likely achieve high levels of protection against hospitalization and death as a result of further vaccination efforts (which may be accelerated by fear of the Delta variant) and natural immunity from prior infection. In addition, boosters, full approval of vaccines (rather than emergency-use authorization), authorization of vaccines for children, and a continuation of the trend toward employer and government mandates and incentives for vaccination are all likely to increase immunity. 50 50. “Q&A: When might the coronavirus vaccines get full approval?,” August 2, 2021; “Covid vaccine mandates,” August 9, 2021; “From offices to restaurants,” August 4, 2021.

Our scenario modeling suggests that although the resulting level of population immunity may not be high enough to achieve herd protection, it would still protect a substantial portion of the population. Most serious cases of COVID-19 would occur in unvaccinated people. Flare-ups and localized epidemics would happen while COVID-19 is managed as an endemic disease, but scenario modeling suggests that these may have less of an effect on the whole of society than the waves seen to date. Booster vaccinations will be important in maintaining immunity levels over time. 51 51. “US to advise boosters,” August 16, 2021. A new variant that substantially evades existing immunity would remain the biggest overall risk.

Countries have varying prospects for reaching the end of the pandemic

Here, we offer a broader geographic view, comparing the current state as of the time of publishing in countries around the world. Our analysis suggests that countries fall into three general groups (within which national conditions can vary to some extent):

1. High-vaccination countries. These countries, primarily in North America and Western Europe, are the ones discussed above.

2. Case controllers. This group includes countries such as Singapore that have been most successful in limiting mortality associated with COVID-19 to date. 52 52. “From pandemic to endemic,” July 1, 2021; Renju Jose, “Sydney daily COVID-19 cases hit record high, more troops to enforce lockdown,” Reuters, August 13, 2021, daypg.com. They have typically maintained tight border restrictions and a strong public-health response to imported cases. Their residents have mostly enjoyed long periods of relative normalcy without public-health restrictions, aside from limits on international travel. Some countries in this group, such as Australia, have recently faced a Delta-driven surge in cases, but in absolute terms the burden of disease remains low relative to other countries. Unless these countries choose to maintain their border restrictions (such as hotel-based quarantine) indefinitely, they might accept the risk of endemic COVID-19 after governments determine that a sufficient portion of the population is vaccinated. 53 53. Salma Khalik, “Moving from Covid-19 pandemic to endemic: Singapore’s strategy and how it can unfold,” Straits Times, July 3, 2021, daypg.com; Peter Collignon, “Australia must eventually face reality: Live with Covid or become a hermit nation,” Guardian, June 15, 2021, daypg.com. The pace of vaccine rollout varies among the countries, but in many cases reopening of borders may not begin until 2022, dependent in part on public-health outcomes for countries in other groups. 54 54. Frances Mao, “‘Fortress Australia’: Why calls to open up borders are meeting resistance,” BBC News, May 26, 2021, daypg.com; Meena Thiruvengadam, “New Zealand to keep its borders closed through the end of 2021,” Travel and Leisure, August 12, 2021, daypg.com. The shift from a zero-COVID-19 goal to an endemic, low-burden goal may be challenging for some countries.

3. At-risk countries. Mainly comprising most lower-income and many middle-income countries, this is a group of nations that have not yet gained access to enough vaccine doses to cover a large portion of their populations. Estimates of their overall immunity remain low enough that there is still a risk of significant waves of disease. Recent projections suggest that it is likely to take until late 2022 or early 2023 for these countries to achieve high vaccine coverage. 55 55. Sara Jerving, “Africa not on track for 10% COVID-19 vaccination rate by end of year,” Devex, July 30, 2021, daypg.com; “Over half a billion COVID-19 vaccine doses administered in WHO South-East Asia Region as countries scale up vaccination efforts,” World Health Organization, August 6, 2021, daypg.com. The possible time frame for them to manage COVID-19 as an endemic disease is less clear.

Globally and nationally, the epidemiological and public-health situation remains dynamic, and the prospects for each country group are subject to uncertainty. Factors that could influence actual outcomes include:

• the potential for new variants to emerge (for example, a variant that evades vaccine-mediated immunity to the extent that it frequently causes severe disease in the vaccinated and spreads widely would likely have the most significant effect on any country’s prospects for reaching the end of the pandemic)
• further evidence of waning natural and vaccine-mediated immunity over time, and challenges with rolling out vaccine boosters quickly enough to maintain immunity
• further challenges with vaccine manufacturing or global rollout
• changes in the ways that countries define an acceptable burden of disease (for example, setting different targets for disease burden in vaccinated and unvaccinated populations)

The surge of COVID-19 cases resulting from the spread of the Delta variant and from vaccine hesitancy brought a sudden, tragic end to the transition toward normalcy that some countries had begun to make. But the United Kingdom’s experience indicates that a transition toward normalcy may yet be possible before long, at least in countries where the vaccine rollout is well under way. Their task will be determining what burden of disease is low enough to warrant lifting of public-health restrictions, and how to manage the public-health impacts of endemic COVID-19. In countries where vaccination rates remain low, the prospects for ending the pandemic remain largely tied to the availability and administration of additional doses. Expanding the international vaccine rollout remains essential to achieving a postpandemic sense of normalcy worldwide.

View more: Post-COVID Conditions: Information for Healthcare Providers

About the authors

Sarun Charumilind is a partner in McKinsey’s Philadelphia office, Matt Craven is a partner in the Silicon Valley office, Jessica Lamb is a partner in the New Jersey office, Adam Sabow is a senior partner in the Chicago office, Shubham Singhal is a senior partner in the Detroit office, and Matt Wilson is a senior partner in the New York office.

The authors wish to thank Xavier Azcue, Marie-Renée B-Lajoie, Andrew Doy, Bruce Jia, and Roxana Pamfil for their contributions to this article.

This article was edited by Josh Rosenfield, an executive editor in the New York office.

March 26, 2021

The fall in COVID-19 cases across much of the world over the past ten weeks signals a new dawn in the fight against the disease. Vaccines are proving effective and rapidly scaling, bending the curve in many geographies. This is a fragile dawn, however, with transmission and deaths still high, unequal access to vaccines, and variants of concern threatening to undo progress to date.

The trajectory of UK and US cases has enabled the beginnings of a transition toward normalcy, 56 56. See our earlier perspectives, below, for definitions of normalcy and herd immunity. When we refer to herd-immunity timelines for a country, we mean the point at which the entire nation or a significant portion reaches herd immunity. the first and more important of the pandemic’s two endpoints. We expect this transition to continue in the second quarter of 2021 and will likely see many aspects of social and economic life return to the prepandemic normal, consistent with UK Prime Minister Johnson’s staged reopening plan for the United Kingdom 57 57. “Lockdown: Boris Johnson unveils plan to end England restrictions by 21 June,” BBC, February 22, 2021, daypg.com. and US President Biden’s goal of a normal Independence Day. 58 58. “Covid pandemic: Biden eyes 4 July as ‘Independence Day’ from virus,” BBC, March 12, 2021, daypg.com. We are more confident in this timeline for the United Kingdom than for the United States, given that the first has already experienced a wave driven by a more infectious variant, whereas the latter could still face one. Parts of the European Union have recently faced setbacks: fewer doses in arms than in the United Kingdom or United States, a new wave of cases, and new lockdowns. A transition toward normalcy is mostly likely in Europe during the late second or third quarter of 2021. The timing will probably vary by country, depending on accelerating vaccine supplies, the impact of vaccinations on hospitalization rates, and the occurrence (or not) of new waves driven by new variants.

Herd immunity, the second endpoint, is most likely in the third quarter for the United Kingdom and the United States and in the fourth quarter for the European Union, with the difference driven by a more limited vaccine availability in the European Union. However, the risks to these timelines are real—herd immunity may not be achieved by the end of the year if vaccine hesitancy is high, if countries experience disruptions in vaccine supply, or if a variant that renders existing vaccines less effective spreads widely. And herd immunity may look different in different parts of the world, ranging from strong nationwide or regional protection to temporary or oscillating immunity to some countries not reaching herd immunity over the medium term.

In this article, we’ll review the developments since our last perspective (January 21), offer an outlook for each of the three geographies, assess risks, and outline what the end of the pandemic might look like.

Recent developments and their impact on timelines

The past month or two have seen seven important developments:

1. Vaccines work. We have growing evidence that vaccines are effective, as real-world data from Israel and the United Kingdom validate the clinical-trial results by showing a sharp reduction in hospitalizations and deaths. 59 59. Jacqui Wise, “Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study,” BMJ, February 25, 2021, Volume 372, Number 8282 daypg.com; Benjamin Mueller, “Vaccines sharply cut coronavirus hospitalization, U.K. studies show,” New York Times, February 22, 2021, daypg.com. Emerging evidence also indicates that vaccines likely reduce transmission considerably, though not to the same degree that they prevent severe disease. 60 60. “Science brief: Background rationale and evidence for public health recommendations for fully vaccinated people,” Centers for Disease Control and Prevention, last updated March 8, 2021, daypg.com.
2. The vaccine rollout is improving. Massive inoculation programs have accelerated, especially in the United Kingdom. As of March 15, the United Kingdom has administered 39 doses per 100 people in the total population; the corresponding figures for the United States and the European Union are 33 and 12 per 100, respectively. 61 61. Hannah Ritchie et al., “Coronavirus (COVID-19) vaccinations,” Our World in Data, last accessed March 15, 2021, daypg.com. Just as important: sentiment about vaccine adoption is improving. 62 62. “Science brief,” last updated March 8, 2021; Matthew Smith, “Europe is becoming more pro-vaccine,” YouGov, January 22, 2021, daypg.com.
3. More vaccines are coming. Johnson & Johnson’s one-shot vaccine appears to be highly effective against severe COVID-19 and received Emergency Use Authorization in the United States on February 27. 63 63. “FDA issues Emergency Use Authorization for third COVID-19 vaccine,” US Food and Drug Administration (FDA), February 27, 2021, daypg.com. Novavax’s vaccine is now in Phase III trials; preliminary results suggest it was highly effective in the United Kingdom but less so in South Africa. 64 64. Nick Paul Taylor, “Novavax COVID-19 vaccine 90% efficacious in phase 3, but protection plummets against one variant,” Fierce Biotech, January 29, 2021, daypg.com. All of that makes it increasingly clear that the United Kingdom and the United States will have enough doses to vaccinate all adults by the end of the second quarter, and Europe should achieve the same milestone by the end of the third quarter, assuming no major vaccines are withdrawn. Further, vaccine trials on children aged 12 and up are well underway, and new trials on babies and children six months and older raise the possibility of pediatric vaccination, which would add to the population that could potentially contribute to herd immunity. 65 65. Peter Loftus, “Moderna is testing its COVID-19 vaccine on young children,” The Wall Street Journal, March 16, 2021, daypg.com.
4. Therapeutics are poised to make more of a difference. A new wave of COVID-19 therapeutics, including those from Eli Lilly, 66 66. “Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19,” Lilly, March 10, 2021, daypg.com. Merck-Ridgeback, 67 67. Ben Adams, “Merck has better luck with 2nd COVID-19 drug attempt as it sees a positive in early molnupiravir data,” Fierce Biotech, March 8, 2021, daypg.com. and Vir Biotechnology, 68 68. Mark Terry, “Vir Bio’s COVID-19 antibody therapy could be great, but will it be too late?,” daypg.com, November 11, 2020, daypg.com. have produced positive data or received Emergency Use Authorization. The emerging data from these treatments suggest they have the potential to materially reduce hospitalizations and deaths for cases that do occur, accelerating a transition toward normalcy.
5. New cases and deaths are lower—but still high. New cases, hospitalizations, and deaths have dropped dramatically—by 79 percent and 89 percent, respectively, in the United States and the United Kingdom from the January peak, as of March 15. 69 69. Jordan Allen et al., “Coronavirus in the U.S.: Latest map and case count,” New York Times, updated March 18, 2021, daypg.com. Based on seven-day averages of cases. This trajectory has amplified discussions of a transition toward normalcy in both countries. The bend in the curve is fragile, however. Much of the decline in Europe has followed strict lockdowns; but lockdowns and other nonpharmaceutical interventions are still confoundingly difficult to get right, and even now, multiple European countries are experiencing upward case trends. And US deaths are still averaging 1,000 per day, many times higher than average daily flu deaths. 70 70. “COVID data tracker,” Centers for Disease Control and Prevention, last accessed March 20, 2021, daypg.com; “Weekly U.S. influenza surveillance report,” Centers for Disease Control and Prevention, last reviewed March 19, 2021, daypg.com.
6. It is increasingly clear that more infectious variants of concern 71 71. “SARS-CoV-2 variants,” Centers for Disease Control and Prevention, last updated March 16, 2021, daypg.com. may drive a new wave of cases in the coming months. The United Kingdom is in a relatively favorable position; cases are declining in spite of the high prevalence of the B.1.1.7 variant, suggesting that the country has a demonstrable ability to control the spread of more infectious variants. In contrast, the United States and parts of the European Union appear to have an increasing prevalence of B.1.1.7. 72 72. Risk assessment: SARS-CoV-2 – increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update, European Centre for Disease Prevention and Control (ECDC), February 2021, daypg.com. The potential for a variant-driven wave of US cases and ongoing spread in Europe in the coming months is real.
7. Variants may also reduce vaccine efficacy or enable reinfection. Data from the AstraZeneca vaccine trial in South Africa highlight the potential for variants such as B.1.351 and P.1 to reduce the efficacy of vaccines. 73 73. Shabhir A. Mahdi et al., “Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant,” The New England Journal of Medicine, March 16, 2021, daypg.com. Other vaccine data, including those from Novavax and Johnson & Johnson, show a more modest reduction in efficacy, especially against severe disease caused by these variants. 74 74. “Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial,” Novavax, January 28, 2021, daypg.com; Carl Zimmer, Noah Weiland, and Sharon LaFraniere, “New analyses show Johnson & Johnson’s one-dose vaccine works well,” New York Times, February 24, 2021, daypg.com. There is also early evidence of mutations arising independently in the United States that may reduce the efficacy of vaccines. 75 75. Eyewitness News, “Coronavirus vaccine updates: Scientists concerned over New York’s ‘escape variant’,” ABC, Inc., WABC-TV New York, March 16, 2021, daypg.com. These variants also appear to be more infectious than the original wild-type strain. These initial findings are based on very small sample sizes and may change as more information becomes available; we still do not know the impact of vaccines against severe disease from these strains. But if these results hold up, the spread of strains against which existing vaccines are substantially less effective would be a significant risk to lives and could delay the end of the pandemic.

What’s the net impact of all these developments? The data continue to indicate, as stated in our earlier perspectives, that a significant transition toward UK and US normalcy will occur in the second quarter of 2021, although the potential for a variant-driven wave in the United States is real and would blunt the transition (Exhibit 1). Potential herd-immunity timelines are bifurcating as a result of growth in variants that may reduce vaccine efficacy. If the variants turn out to be a minor factor (they only reduce vaccine efficacy modestly, or they don’t spread widely), then herd immunity in the second half of the year is likely for both countries—and is more likely in the third quarter than the fourth. However, if the impact of these variants is significant, we could see timelines significantly prolonging into late 2021 or beyond.

How does this vary by geography?

Most of our analysis in this series has focused on the United Kingdom and the United States, which continue to move down a similar path. The end of Europe’s pandemic may come somewhat later, and other countries’ outlooks will depend on several variables.

European Union. Here, as in other regions, the timing of access to vaccines will be the biggest driver of the end of the pandemic. Levels of natural immunity from prior infection vary within the European Union but are generally in the same range as in the United Kingdom and the United States. 76 76. SeroTracker, last accessed March 15, 2021, daypg.com. Seasonality is likely to work in similar ways. And public interest in vaccination appears to be similar too, even in countries such as France, where interest in vaccination was significantly lower than in other countries in the region but may now be improving. 77 77. “Global attitudes: COVID-19 vaccines,” Ipsos, February 9, 2021, daypg.com; Yasmeen Serhan, “The vaccine-hesitant man of Europe,” The Atlantic, March 18, 2021, daypg.com. The prevalence of the more infectious B.1.1.7 variant varies by country; most countries with cases are between the high UK levels and lower US levels.

Exhibit 2 lays out the likely timing of vaccine availability in the European Union. Broadly speaking, availability will be similar to that of the United Kingdom and the United States, but EU countries may need to wait a few months longer to vaccinate all adults. Please note that this would be subject to change and further delay if the Oxford-AstraZeneca vaccine remains suspended in multiple countries following concerns about blood clots; WHO has confirmed its continued support of the vaccine. 78 78. “WHO statement on AstraZeneca COVID-19 vaccine safety signals,” WHO, March 17, 2021, daypg.com.

Given that sufficient vaccine doses are available to vaccinate the highest-risk populations in the coming months, we expect to see the EU transition to normalcy during the second quarter of the year, although the start of this transition may be delayed until late in the quarter by a new wave of cases in some countries. A key difference for the European Union, as compared with the United Kingdom and the United States: herd immunity is more likely in the fourth quarter than the third quarter, given the likely timeline of vaccine delivery (Exhibit 3).

Rest of the world. While the European Union, the United Kingdom, and the United States have had broadly similar COVID-19 experiences, other parts of the world look very different. Countries like New Zealand have avoided significant COVID-19-associated mortality but appear to be further from herd immunity because so few New Zealanders have infection-driven immunity to SARS-CoV-2. On the other hand, if vaccine uptake is fast, New Zealand might achieve a longer-lasting vaccine-based herd immunity. A second factor is seasonality: the timing of seasonality-driven changes will be different in tropical locations and the Southern Hemisphere. A third is demographics: while the younger populations of many lower-income countries have led to lower COVID-19-associated mortality, they also make it harder for adult-only vaccination programs to drive herd immunity. And perhaps most importantly for timelines, access to vaccines is unequal. While COVAX and other access initiatives are working to close the gap, many low-income countries may not receive enough doses to vaccinate all adults until well into 2022. 79 79. “More than 85 poor countries will not have widespread access to coronavirus vaccines before 2023,” Economist Intelligence Unit, January 27, 2021, daypg.com. The world is on pace to manufacture enough doses for 80 percent of the global population—or close to 100 percent of the adult population—by the end of 2021, but the distribution of these doses may continue to be asymmetric.

Exhibit 4 provides a global view of seven factors that are likely to drive herd-immunity timelines for the rest of the world. These factors include the following:

• Population vaccinated—the proportion of people who have received the vaccine so far
• Vaccine courses secured—the additional supplies for which a country has contracted
• Supply-chain readiness
• Consumer vaccine sentiment—the public’s willingness to be vaccinated
• Population under 19 years of age—a greater proportion of children makes a transition toward normalcy easier to achieve but herd immunity more difficult
• Natural immunity, or the rate of prior COVID-19 infection—higher historical infection rates decrease the vaccination rate needed to achieve herd immunity
• Prevalence of variants of concern

Risks to herd immunity

Herd immunity requires that enough people be simultaneously immune to SARS-CoV-2 to prevent widespread ongoing transmission. While data indicate that the most likely scenario is to reach this state on the timelines described above, five risks could delay progress.

First, vaccine adoption may prove lower than expected. That could happen if a real or perceived safety issue increases hesitancy or if younger populations see little reason to be vaccinated once older cohorts are protected and a transition toward normalcy is well underway. Second, herd immunity relies on the efficacy of vaccines at reducing transmission (rather than the usually reported efficacy at preventing disease in the vaccinated person). While initial data suggest that COVID-19 vaccines do block significant transmission, 80 80. Smriti Mallapaty, “Can COVID vaccines stop transmission? Scientists race to find answers,” Nature, February 19, 2021, daypg.com. the efficacy rate may not prove high enough to drive herd immunity. Third, the duration of vaccine-mediated immunity may prove shorter than anticipated, making it hard to reach the necessary threshold for simultaneous immunity. Fourth, supply-chain disruptions and delays are real, and could produce supply shocks and interfere with timelines. Fifth, and most concerning, variants that reduce the efficacy of vaccines or the benefits of natural immunity may spread widely. Some initial data offer concerning evidence that B.1.351 and P.1 may be examples of such variants, although recent Novavax data (with a small sample size) offer some reassurance that its vaccine is effective against severe disease caused by B1.351. 81 81. Lee Landenberger, “Novavax’s COVID-19 vaccine shows 100% protection against severe disease,” March 12, 2021, daypg.com. Similarly, limited data from the Pfizer-BioNTech and AstraZeneca vaccines show evidence of some protection against P.1. 82 82. “Existing vaccines may protect against the Brazilian coronavirus variant,” University of Oxford, March 18, 2021, daypg.com.

These five factors combined mean that there is still a meaningful chance that herd immunity is not reached in the medium term.

From theory to practice: What the ‘end’ might look like

The pandemic’s two endpoints, a transition toward normalcy and herd immunity, may look different in different places. As the name implies, a transition will include a series of steps that will gradually normalize aspects of social and economic life. The order and pace of these steps will vary by geography. Not everyone will immediately resume all of their prepandemic activities; rather, there will be a noticeable shift toward more of them. Steps may include a return to fully in-classroom education, fewer restrictions on the operations of bars and restaurants, more gatherings with larger groups of people, the reopening of offices, and fewer prohibitions on interregional or international travel. The United Kingdom’s plan for reopening provides an example of the stepwise manner in which a transition to normalcy is likely to occur. 83 83. “Lockdown: Boris Johnson unveils plan to end England restrictions by 21 June,” February 22, 2021.

Herd immunity will represent a more definitive end to the pandemic. Isolated cases may still occur—indeed, the virus may continue to circulate for one or more quarters after herd immunity is reached. But with herd immunity, population-wide public-health measures can be phased out. As populations get closer to this state, it may be helpful to introduce some nuance to what we mean by the term.

1. Nationwide herd immunity. The full population is well protected so that the country experiences, at most, occasional small flare-ups of disease. This scenario is most likely in smaller countries where immunity to COVID-19 can become uniformly high.
2. Regional herd immunity. Some regions, states, or cities are well protected, while others experience ongoing outbreaks of COVID-19. In large, diverse countries like the United States, this situation is especially easy to imagine.
3. Temporary herd immunity. A population or region achieves herd immunity for some period, but as variants are introduced, against which prior immunity is less effective, a new wave of cases is launched. Another potential trigger for such a wave could come as immunity (particularly natural immunity) wanes. As the number of new cases of COVID-19 falls globally, the rate of emergence of important variants should also decrease, but some risk will remain.
4. Endemicity. A region fails to achieve herd immunity. Endemicity is most likely in places where vaccine access is limited, where few people choose to be vaccinated, if the duration of immunity is short, or variants that reduce vaccine efficacy are common and widespread. Endemicity might include cyclic, seasonal waves of disease, broadly similar to the flu, or a multiyear cycle of resurgence.

The next few years are likely to see a combination of some or all of these options around the world. Given the likely timing of herd immunity in various geographies and the uncertain duration of protection from vaccines (both duration of immune response and efficacy versus new variants), it is likely that some measures such as booster vaccines are likely to be required indefinitely. Herd immunity is not the same as eradication. SARS-CoV-2 will continue to exist. Even when a country reaches herd immunity, ongoing surveillance, booster vaccines, and potentially other measures may be needed.

A year ago, the world was coming to terms with a long, difficult journey ahead. Twelve months later, the end of the pandemic is in sight for some parts of the world. It’s much too soon to declare victory, however. We hope that our perspectives prove useful to leaders as they set policy and strategy; we will continue to update the series.

Download the article here.

View more: Post-COVID Conditions: Information for Healthcare Providers

About the authors

Sarun Charumilind and Jessica Lamb are both partners in McKinsey’s Philadelphia office, Matt Craven is a partner in the Silicon Valley office, Adam Sabow is a senior partner in the Chicago office, and Matt Wilson is a senior partner in the New York office.

The authors wish to thank Xavier Azcue for his contributions to this article.

This article was edited by Mark Staples, an executive editor in the New York office.

January 20, 2021

This article updates our earlier perspectives on when the coronavirus pandemic will end. Transition toward normalcy in the United States remains most likely in the second quarter of 2021 and herd immunity in the third and fourth quarters, but the emergence of new strains and a slow start to vaccine rollout raise real risks to both timelines. We also add a perspective for the United Kingdom.

The past five weeks have brought an array of conflicting news on the COVID-19 pandemic, affecting our estimates about when the coronavirus pandemic will end. Margaret Keenan, a British nonagenarian, made history on December 8 by becoming the first person to receive the Pfizer-BioNTech vaccine for SARS-CoV-2 outside a clinical trial. 84 84. “Covid-19 vaccine: First person receives Pfizer jab in UK,” BBC, December 8, 2020, daypg.com/news. Since then, several other vaccines have been authorized for use around the world. Sufficient doses are likely to be available to vaccinate high-risk populations in the United States in the first half of 2021. In parallel, however, more-infectious strains of the virus have been detected in South Africa, the United Kingdom, and elsewhere and have spread to an increasing number of countries. 85 85. Miriam Berger, “U.K. variant continues to spread around the world as coronavirus pandemic enters 2021,” Washington Post, January 2, 2021, daypg.com. And the initial rollout of vaccines has been slower than hoped in many places. 86 86. Michelle R. Smith, “Governors scramble to speed vaccine effort after slow start,” Associated Press, January 6, 2021, daypg.com.

While the United States could still achieve herd immunity in the third or fourth quarter of 2021 (in line with the peak probability in our previous estimates), the emergence of more-infectious variants of SARS-CoV-2 increases the risk that this milestone will not be achieved until later. More-infectious viruses require that a higher percentage of people be simultaneously immune to reach herd immunity. 87 87. Ken Eames, Paul Fine, and David L. Heymann, ‘‘‘Herd immunity’: A rough guide,” Clinical Infectious Diseases, 2011, Volume 52, Number 7, pp. 911-6, daypg.com. While a more infectious variant likely means more people are acquiring natural immunity through infection (despite ongoing efforts to minimize new cases), the net impact of more-infectious strains is likely to be that a higher portion of the population needs to be vaccinated, which may take more time.

We still believe that the United States can transition toward normalcy during the second quarter of 2021, but the same risks also threaten this timeline. A transition toward normalcy would be driven by a combination of seasonality aiding a decline in cases and early vaccine doses helping reduce mortality by protecting those at greatest risk of serious illness. As COVID-19’s impact on health wanes, we are likely to see greater normalization of social and economic life. Data on the availability of vaccine doses in the United States increase confidence that this is possible, but the slow start to the vaccine rollout reinforces that success is by no means guaranteed.

This article describes “most likely” timelines for when the coronavirus pandemic will end. It is now harder to imagine the United States or United Kingdom transitioning to normalcy before second quarter 2021 or reaching herd immunity before third quarter 2021. But a number of other factors could delay the timelines beyond those described, including unexpected safety issues emerging with early vaccines, significant manufacturing or supply-chain delays, continued slow adoption, further mutation, or a shorter-than-anticipated duration of vaccine-conferred immunity. Herd immunity will also require vaccines to be effective in reducing transmission of SARS-CoV-2, not just in protecting vaccinated individuals from getting sick. This is likely, but has not yet been proven at scale. 88 88. Sabin Russell, “Vaccines stop COVID-19 symptoms, but do they stop transmission?,” Fred Hutch News Service, December 16, 2020, daypg.com.

WATCH A McKinsey Live event on ‘COVID-19 vaccines are here. What does that mean for your organization?’ Click here

Herd immunity

More-infectious strains raise the bar

Herd immunity to a pathogen is achieved when a sufficient portion of a population is simultaneously immune to prevent sustained transmission. The threshold to achieve it is governed by a number of factors, including the transmissibility of the disease. 89 89. Eames, Fine, and Heymann, ‘‘‘Herd immunity’: A rough guide,” pp. 911-6. More-infectious strains of SARS-CoV-2 therefore raise the bar on herd immunity. The virus has been mutating since it was identified a year ago. The concerning development in recent weeks has been the confirmation of new strains in South Africa, the United Kingdom, and elsewhere that combine multiple mutations and have different profiles. While data are still emerging, initial estimates suggest that the transmissibility rate of the UK strain is 40 to 80 percent higher than that of the original SARS-CoV-2 strain, and that transmission rates could be higher among children too. 90 90. Erik Volz et al., Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data, Imperial College London, December 2020, daypg.com. 91 91. Nicholas Davies et al., Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England, Centre for Mathematical Modelling of Infectious Diseases, December 2020, daypg.com. There is no evidence of higher case fatality with either new strain, but there are fears that new strains may affect how antibodies bind to the virus and may reduce the efficacy of vaccines or antibody treatments developed over the past few months. More data are likely to emerge on this in the weeks ahead.

If these strains become dominant, they may cause a material delay in reaching herd immunity. While many people are acquiring natural immunity through infection, variants with enhanced transmissibility, if they predominate among all strains, could increase the proportion of people who need to be simultaneously immune to achieve herd immunity by ten to 20 percentage points, and increase vaccine coverage levels needed to 65 to 80 percent of the population (or 78 to 95 percent of those over 12 years old). 92 92. Based on a reproduction number (R0) of 2.4 for the original strain and assuming that the herd immunity threshold can be approximated using the formula 1- (1/R0). For more, see Eames, Fine, and Heymann, ‘‘‘Herd immunity’: A rough guide,” pp. 911-6. Estimates of increased vaccine coverage needed are based on R0 = 3.36-4.32, which is 40-80% greater than R0 of 2.4. More detail is shown in Exhibit 1 below.

Exhibit 1 We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

Vaccinating more people is a nonlinear challenge. Consumer surveys suggest that a portion of the population is cautious about vaccination. Increasing coverage from 70 to 80 percent is therefore harder than increasing from 60 to 70 percent. Because more-transmissible variants raise herd-immunity thresholds, there will also be less tolerance for low vaccine effectiveness. For example, with a variant that is 40 to 80 percent more transmissible, vaccine efficacy of 90 percent would require 83 to 100 percent of those over 12 to be vaccinated; efficacy of anything less than 75 percent would make herd immunity likely unachievable through vaccination of only those over 12.

While the variant of concern appears to be most widespread in the United Kingdom, it has been detected in over 30 countries, many of which (including the United States) have limited capacity for genetic sequencing. As a result, we may be significantly underestimating its spread. 93 93. Miriam Berger, “U.K. variant continues to spread around the world as coronavirus pandemic enters 2021,” Washington Post, Jan 2, 2021, daypg.com. 94 94. Carl Zimmer, “U.S. is blind to contagious new virus variant, scientists warn,” New York Times, January 6, 2021, daypg.com. The strain is likely to continue spreading in the coming months, propelled by its reproductive advantage over the original. This appears to have occurred in southern England over the past few months. If new strains predominate, they could lead to a longer timeline to herd immunity.

Vaccine rollout: A slow start, but there is still time to improve

The speed of COVID-19 vaccine development has been an unqualified success. The approval, in at least one country, of vaccines made by Pfizer and BioNTech, Moderna, Oxford and AstraZeneca, Sinopharm, Serum Institute, Bharat Biotech, Gamaleya, and others within a year of viral sequencing smashed all records for development timelines. But rollout is off to a slow start. While countries such as Israel have shown what is possible, the United States has fallen behind its targets. 95 95. “Coronavirus: Israel leads vaccine race with 12% given jab,” BBC, January 3, 2021, daypg.com. 96 96. Michelle R. Smith, “Governors scramble to speed vaccine effort after slow start,” Associated Press, January 6, 2021, daypg.com. It is still early days, and there is time to accelerate, but there is little margin for error if the United States is to achieve herd immunity in third quarter 2021. In addition, not all regions are adhering closely to manufacturer dosing protocols—for example, delaying second doses or giving a first dose from one manufacturer followed by a second from another—and the impact of that is unclear. These approaches could reduce mortality in the short term by broadening access, but they could also delay herd immunity if, for example, a delayed second dose reduces efficacy. It’s also possible that once most people in the highest-risk groups have received vaccinations, the pace of vaccination will slow if lower-risk groups do not embrace the opportunity.

We believe that herd immunity in the United States is still most likely in third or fourth quarter 2021, but that the chance of delay until first quarter 2022 or beyond has increased (Exhibit 2). There is relatively little chance of achieving herd immunity before then. Even later herd immunity remains possible if other challenges arise, especially vaccine safety concerns or ambivalence to vaccination following a transition toward normalcy. This potential delay represents a call to action for policy makers, both in terms of the pace of the vaccine rollout and how new strains are managed.

Increasing recognition of medium-term endemicity

While many parts of the world are expected to reach herd immunity against COVID-19, there is increasing consensus that globally, SARS-CoV-2 is likely to remain endemic in the medium term. David Heymann, the chairman of the World Health Organization’s Strategic and Technical Advisory Group for Infectious Hazards, noted in December that endemicity may be the “destiny” of this virus. 97 97. Melissa Davey, “WHO warns Covid-19 pandemic is ‘not necessarily the big one,’” Guardian, December 29, 2020, daypg.com. This might make COVID-19 analogous to measles—a disease that causes intermittent, limited outbreaks in countries with well-developed vaccination programs but significant ongoing disease in parts of the world where access to vaccines is more limited. It is also possible that COVID-19 will be seasonal, with predictable annual peaks in parts of the world where it is endemic. 98 98. Apoorva Mandavilli, “The future of the coronavirus? An annoying childhood infection,” New York Times, January 12, 2021, daypg.com.

Transition toward normalcy

A transition toward normalcy will occur when COVID-19 mortality falls and the disease is de-exceptionalized in society. COVID-19 will not disappear during this transition, but will become a more normal part of the baseline disease burden in society (like flu, for example), rather than a special threat requiring exceptional societal response. During this transition, controlling the spread of SARS-CoV-2 will still require public-health measures (such as continued COVID-19 testing and mask use in many settings), but mortality will fall significantly, allowing greater normalization of business and social activities. This will be driven by a combination of early vaccine rollout (which, being directed first at those at greatest risk, should reduce deaths faster than cases), seasonality, increasing natural immunity, and stronger public-health response.

Increasing clarity on the availability of vaccine doses during the first half of 2021 in the United States improves the odds of an early transition toward normalcy. As Exhibit 3 shows, Pfizer and Moderna are expected to deliver sufficient vaccine doses to vaccinate all high-risk Americans during the first half of the year. This does not account for other vaccines that are likely to become available, including those approved in other markets (for example, Oxford-AstraZeneca) or others that are likely to report clinical trial data in the first quarter of 2021 (including Johnson & Johnson and Novavax). Older people are generally more willing to be vaccinated than the general population. However, slow initial rollout of the vaccines and the spread of more infectious variants increase the risk that significant mortality continues in the second quarter, blunting a transition to normalcy.

Taking these variables into account, we still believe that a transition toward normalcy is likely during second quarter for the United States, but that downside risks have increased. If early vaccine doses reach a significant percentage of high-risk elderly individuals by the end of quarter one, the combination of protecting these groups and the arrival of spring in the northern hemisphere should improve the situation compared with where the United States is now. Depending on vaccination progress over the summer (whether the United States is on the earlier or later end of the herd immunity window), there may be a smaller fall wave of disease in third to fourth quarter 2021.

While the potential for a transition toward normalcy in just a few months is encouraging, many signs suggest that the next six to eight weeks will be difficult. Case and death numbers are at or near all-time highs in many locations, new variants may accelerate short-term transmission, and vaccine rollout has not yet proceeded far enough to protect much of the population. Strong public-health measures will remain critical to saving lives during this period.

Timeline for the United Kingdom

We see similar dynamics in the United Kingdom. Three factors lead us to believe that timelines for herd immunity and transition toward normalcy in the United Kingdom will be similar to those in the United States. First, access to vaccines is sufficient to immunize a large percentage of both the US and UK populations during 2021. Second, public willingness to be vaccinated is generally similar between the two countries. 99 99. Jeffrey V. Lazarus et al., “A global survey of potential acceptance of a COVID-19 vaccine,” Nature Medicine, 2020, daypg.com. Third, the fraction of US and UK residents who already have natural immunity from prior infection is in the same range (with significant variability among regions within countries). 100 100. “SeroTracker,” Public Health Agency of Canada, accessed 1/12/21, daypg.com.

The variant of concern represents a potential source of difference. While it is known to be highly prevalent in the United Kingdom and present in the United States, there is a significant chance that it will predominate throughout the United States over the coming months. All else being equal, countries with a higher proportion of more-infectious variants—assuming they increase public-health measures to handle them—are likely to achieve herd immunity later.

We will add a perspective for other parts of the world, including the rest of Western Europe, in future updates to this article.

Twelve months ago, most people weren’t thinking about COVID-19. Today, much of the world is intensely focused on it, but we can reasonably expect the imminent threat to abate. Much work remains to be done. In the short term, public-health measures can help control the pandemic, but even when herd immunity is achieved, managing the risk of COVID-19 will require monitoring, potential revaccination, and treatment of isolated cases. Every country has its own COVID-19 story, but those stories will eventually reach some kind of ending.

Download the article here.

View more: Post-COVID Conditions: Information for Healthcare Providers

About the authors

Sarun Charumilind and Jessica Lamb are both partners in McKinsey’s Philadelphia office, Matt Craven is a partner in the Silicon Valley office, Adam Sabow is a senior partner in the Chicago office, and Matt Wilson is a senior partner in the New York office.

View more: Kims Fans Are Losing It Over Her Posting an Ariana Lyric on Instagram After Pete Deleted His Account

The authors wish to thank Xavier Azcue, Brian Hencke, David Meredith, Michalis Michaelides, Anthony Ramirez, Virginia Simmons, Konstantinos Tsakalis, and Lieven Van der Veken for their contributions to this article.

November 23, 2020

Our November 23 update takes on the questions raised by recent news: When will vaccines be available? And is the end of COVID-19 nearer?

Since we published our first outlook, on September 21st, the COVID-19 pandemic has raged on, with more than 25 million additional cases and more than 400,000 additional deaths. While the situation looks somewhat better in parts of the Southern Hemisphere, much of Europe and North America is in the midst of a “fall wave,” with the prospect of a difficult winter ahead. Yet the past two weeks have brought renewed hope, headlined by final data from the Pfizer/BioNTech 101 101. “Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints,” Pfizer, November 18, 2020, daypg.com. vaccine trial and interim data from the Moderna trial, both showing efficacy of approximately 95 percent 102 102. “Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study, Moderna, November 16, 2020, daypg.com. ; and progress on therapeutics. Is an earlier end to the pandemic now more likely?

The short answer is that the latest developments serve mainly to reduce the uncertainty of the timeline (Exhibit 1). The positive readouts from the vaccine trials mean that the United States will most likely reach an epidemiological end to the pandemic (herd immunity) in Q3 or Q4 2021. An earlier timeline to reach herd immunity—for example, Q1/Q2 of 2021—is now less likely, as is a later timeline (2022). If we are able to pair these vaccines with more effective implementation of public-health measures and effective scale-up of new treatments and diagnostics, alongside the benefits of seasonality, we may also be able to reduce mortality enough in Q2 to enable the United States to transition toward normalcy. (See sidebar “Two endpoints” for our definitions.)

A secondary effect of the recent vaccine trials is to make Q3 2021 more likely for herd immunity than Q4. That said, major questions are still outstanding, even about vaccines, such as long-term safety, timely and effective distribution, and vaccine acceptance by the population, to say nothing of lingering epidemiological questions such as the duration of immunity.

These are estimates for the United States, which is likely to have fast and ready access to vaccines. We will consider timelines for other countries in forthcoming updates; they will vary based on the timing of access and distribution of vaccines and other factors. In this update, we review the most recent findings, look deeper at five implications of the ongoing scientific research, and discuss why our timeline estimates have not shifted meaningfully.

Revelations from vaccine and antibody trials

The world has cheered announcements over the past two weeks by Pfizer and its partner BioNTech, and from Moderna. Their COVID-19 vaccine candidates are showing efficacy rates that are higher than many dared hope for. One is a final result, and the other is an initial result whose sample size is large enough to give reasonable confidence in the data. At about 95 percent, efficacy is higher than expected by most experts. 103 103. “Pfizer vaccine efficacy could be a ‘game changer,’” Cornell University, November 8, 2020, daypg.com. It exceeds the optimistic case that we included in our September article. Higher efficacy provides greater benefit to any vaccinated individual and may help to encourage uptake among some segments of the population. It also reduces the fraction of the population required to reach herd immunity. Moderna also announced that its vaccine is more shelf-stable than expected and would need only refrigeration to keep it stable for 30 days—another piece of good news. Finally, there are a number of other vaccines in late-stage trials from which data is expected in the coming months.

Caution is still warranted. The safety records of the Pfizer and Moderna vaccines appear promising so far (no serious side effects reported), but the coming months will provide a fuller picture as the sample size grows. We don’t yet know how long the protection the vaccines offer will last. The Pfizer trial has enrolled some children (ages 12 and older), but efficacy in those under 18 remains unclear.

Beyond vaccines, science is also progressing in therapeutics for COVID-19. For example, Eli Lilly’s antibody bamlanivimab was granted Emergency Use Authorization (EUA) by the US Food and Drug Administration on November 9, 104 104. “Coronavirus (COVID-19) update: FDA authorizes monoclonal antibody for treatment of COVID-19,” US Food and Drug Administration, November 9, 2020, daypg.com. and Regeneron’s EUA for its antibody cocktail REGN-COV2 for EUA was approved on November 22. Emerging data on these antibodies suggest that they can reduce the need for hospitalization of high-risk patients, and hold potential for post-exposure prophylaxis. 105 105. Laura DeFranceso, “COVID-19 antibodies on trial,” Nature, October 2020, daypg.com; “Coronavirus (COVID-19) update,” FDA, November 2020. While they are not recommended for use in hospitalized patients, these antibodies add to the growing armamentarium of treatments and protocols for COVID-19, where every incremental advance could help to reduce mortality. Collectively, these treatments and changes in clinical practice have lowered mortality for those hospitalized by 18 percent or more. 106 106. Leora Horwitz et al., “Trends in COVID-19 risk-adjusted mortality rates,” Journal of Hospital Medicine, October 2020, daypg.com.

Looking deep into the data

Research and findings of the past two months have shed light on a number of uncertainties and in some cases have raised new questions. Here we review five implications; each has helped refine our probability estimates for the COVID-19 pandemic timeline.

Vaccine age restrictions elevate coverage requirements to reach herd immunity

It appears that the two vaccines mentioned will be indicated first for use in adults. 107 107. Development and licensure of vaccines to prevent COVID-19: Guidance for industry, US Food and Drug Administration, June 2020, daypg.com. It’s not clear when use in children will be indicated. One consequence is that the vaccines’ contribution to population-wide herd immunity will depend on adults, at least until vaccines are approved for use in younger populations. If vaccines are efficacious, safe, and distributed to all ages, vaccine coverage rates of about 45 to 65 percent—in combination with projected levels of natural immunity—could achieve herd immunity (Exhibit 2).

Exhibit 2 We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

On the other hand, if vaccines are efficacious but distributed only to adults, who comprise only 76 percent of the US population, 108 108. Age and sex composition in the United States: 2019, US Census Bureau, accessed November 15, 2020, daypg.com. then higher vaccine coverage rates—approximately 60 to 85 percent—could be required to achieve herd immunity.

Another consequence is that older children, who have twice the COVID-19 incidence of younger children and who have higher viral loads (and therefore greater potential contagiousness) than adults 109 109. Rebecca Leeb et al., COVID-19 trends among school-aged children—United States, March 1-September 19, 2020, Centers for Disease Control and Prevention, October 2, 2020, daypg.com; Lael Yonker et al., “Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Clinical presentation, infectivity, and immune response,” Journal of Pediatrics, August 19, 2020 daypg.com. may not have immediate access to vaccines.

We recognize that calculating herd immunity thresholds is complex. Basic formulas fail to account for variations in the way populations interact in different places. 110 110. Kevin Hartnett, “The tricky math of herd immunity for COVID-19,” Quanta Magazine, June 30, 2020, daypg.com. For this reason we include relatively wide ranges.

Unclear impact of vaccines on transmission could raise the bar on coverage

Vaccine trials and regulatory approval will be based on safety and efficacy in reducing virologically confirmed, symptomatic disease among individuals. 111 111. Marc Lipsitch et al., “Understanding COVID-19 vaccine efficacy,” Science, November 13, 2020, daypg.com. That’s not the same as reducing transmission. This distinction will have much to say about whether the United States reaches normalcy in Q2 or Q3 of 2021. In practice, we have data on whether people who are vaccinated are less likely to get sick with COVID-19 (and less likely to get severe disease), but we won’t have data on how likely they are to transmit to others. It’s an important distinction because what will drive herd immunity is reduction in transmission. If vaccines are only 75 percent effective at reducing transmission, then coverage of about 60 to 80 percent of the population will be needed for herd immunity. And if a vaccine is only 50 percent effective at reducing transmission, coverage of over 90 percent would be required (Exhibit 3).

Wide variations in local seroprevalence suggest heterogeneous paths to herd immunity

Improved estimates of seroprevalence are increasingly available for many regions. They vary widely, from as low as 1 to 2 percent in some states like Colorado and Kansas to 14 to 20 percent in New Jersey and New York. 112 112. “Nationwide commercial laboratory seroprevalence survey,” Centers for Disease Control and Prevention, accessed November 15, 2020, daypg.com. Because achieving herd immunity relies in part on a population’s natural immunity, it appears that some locations are closer to herd immunity than others (and have likely also experienced worse impact on public health to date.) Based on a range of likely vaccine scenarios and the fact that those with prior exposure to SARS-CoV-2 will still be eligible for vaccination, every ten percentage-point increase in seroprevalence could roughly translate into a one-month acceleration of the timeline to the epidemiological endpoint.

However, it is possible that areas with higher seroprevalence may also have higher thresholds for herd immunity, because their populations may mix more, 113 113. Anthony Ives and Claudio Bozzuto, “State-by-state estimates of R0 at the start of COVID-19 outbreaks in the USA,” MedRxiv, May 27, 2020, daypg.com. which could have contributed to higher seroprevalence to begin with. If that’s true, then while they are further along, they may also have further to go. Well-executed distribution of effective vaccines will still be paramount.

Potentially shorter duration of immunity could prolong the path to the ‘end’

Earlier in the pandemic, it was unclear how long immunity after COVID-19 infection would last. Duration of immunity matters, obviously; for instance, our modeling suggests that if natural immunity to COVID-19 lasts six to nine months, as opposed to multiple years (like tetanus) or lifelong (like measles), herd immunity is unlikely to be achieved unless adult vaccination rates approach 85 percent. While COVID-19 reinfection is documented but rare, there are now population-level studies that question the durability of immunity. Antibody levels may wane after just two months, according to some studies, while a United Kingdom population-monitoring effort reported that antibody prevalence fell by 26 percent over three months. 114 114. F. Javier Ibarrondo et al., “Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19,” New England Journal of Medicine, September 10, 2020, daypg.com; Helen Ward et al., “Declining prevalence of antibody positivity to SARS-CoV-2: A community study of 365,000 adults,” MedRxiv, October 27, 2020, daypg.com. The relationship between waning antibodies and reinfection risk remains unclear. Other research suggests that even with waning levels of COVID-19 antibodies, the immune system may still be able to mount a response through other specific B-cell and T-cell immune pathways, where emerging evidence shows much greater durability after six months. 115 115. Rebecca Cox and Karl Brokstad, “Not just antibodies: B cells and T cells mediate immunity to COVID-19,” Nature Reviews Immunology, August 24, 2020, daypg.com; Jennifer Dan et al., “Immunological memory to SARS-CoV-2 assessed for greater than six months after infection,” BioRxiv, November 16, 2020, daypg.com.

Manufacturing and supply issues are clearer, but have not vanished

If the initial efficacy data from the Pfizer and Moderna vaccine trials hold up, and if no significant safety issues emerge, then initial demand is likely to be high. Two promising candidates are better than one, but supplies will undoubtedly be constrained in the months following EUA and approval. The situation may be dynamic as vaccines are approved at different times, each with its own considerations in manufacturing and distribution. For example, current data suggest that Moderna’s vaccine is stable at refrigerated temperatures (2 to 8 degrees Celsius) for 30 days and six months at -20 degrees Celsius. Pfizer’s vaccine can be stored in conventional freezers for up to five days, or in its custom shipping coolers for up to 15 days with appropriate handling. Longer-term storage requires freezing at -70 degrees Celsius, requiring special equipment. 116 116. Katie Thomas, “New Pfizer results: Coronavirus vaccine is safe and 95% effective,” New York Times, November 18, 2020, daypg.com. Both Pfizer’s and Moderna’s would be two-dose vaccines, necessitating rigorous follow-up for series completion. These and other complexities create risk of delay. Timelines to reach the desired coverage threshold will be affected by health systems’ abilities to adapt to changing needs and updated information.

The pandemic’s end is more certain, and may be a little nearer

Given all of these variables, where do we net out?

While the winter of 2020/2021 in the Northern Hemisphere will be challenging, we are likely to see mortality rates fall in Q2 (or possibly late Q1) of 2021. Seasonality and associated changes in behavior will begin to work again in our favor in the spring, and the combination of early doses of vaccines targeted to those at highest risk (and the benefits of the Pfizer and Moderna vaccines in reducing severe disease), advances in treatment, expanded use of diagnostics, and better implementation of public-health measures should serve to significantly reduce deaths from COVID-19 in the second quarter. At this stage, when monthly mortality from COVID-19 may start to resemble that of flu in an average year, we may see a transition toward normalcy, albeit with public-health measures still in place.

We are as excited as others about the stunning developments in vaccines. We think Q3 or Q4 of 2021 are even more likely to see herd immunity in the United States. This is based on EUA of one or more high-efficacy vaccines in December 2020 or January 2021, as manufacturers are targeting 117 117. “Pfizer and BioNTech to submit Emergency Use Authorization request today to the US FDA for COVID-19 vaccine,” Pfizer, November 20, 2020, daypg.com; “Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study,” Moderna, November 16, 2020, daypg.com. ; distribution to people at highest risk (healthcare workers, the elderly, and those with comorbidities) in the early months of 2021 118 118. The COVID-19 vaccination program interim operational guidance for jurisdictions playbook, Centers for Disease Control and Prevention, October 29, 2020, daypg.com. ;full approval of a vaccine in March or April; and then widespread rollout. Our estimates of three to eight months for manufacturing, distribution, and adoption of sufficient vaccine doses to achieve herd immunity remain unchanged, and suggest that the milestone may be reached between July and December 2021.

Recent developments suggest that herd immunity is less likely to come in early 2021, given that vaccines are arriving roughly on the expected timeline; and the downside scenario stretching into 2022 is also less likely, since efficacy is clearer. The new vaccines may slightly accelerate the timeline—the ongoing surge in cases will likely continue into winter, which would increase natural immunity levels going into Q2. Further, higher-than-expected efficacy may help offset coverage challenges that surveys have suggested. Those two factors could advance the timeline, and make Q3 a little more likely than Q4.

Our estimate is based on the widest possible reading of the current scientific literature and our discussions with public-health experts in the United States and around the world. It’s possible that unforeseen developments such as significantly more infections than expected this winter could lead to earlier herd immunity. And real downside risk remains, especially with respect to duration of immunity and long-term vaccine safety (given the limited data available so far). Herd immunity might not be reached until 2022 or beyond.

Even when herd immunity is achieved, ongoing monitoring, potential revaccination, and treatment of isolated cases will still be needed to control the risk of COVID-19. But these would fall into the category of “normal” infectious disease management—not the society-altering interventions we have all lived through this year. The short term will be hard, but we can reasonably hope for an end to the pandemic in 2021.

Download the article here.

View more: Post-COVID Conditions: Information for Healthcare Providers

About the authors

Sarun Charumilind and Jessica Lamb are both partners in McKinsey’s Philadelphia office, Matt Craven is a partner in the Silicon Valley office, Adam Sabow is a senior partner in the Chicago office, and Matt Wilson is a senior partner in the New York office.

The authors wish to thank Gaurav Agrawal, Xavier Azcue, Jennifer Heller, Anthony Ramirez, Shubham Singhal, and Rodney Zemmel for their contributions to this article.

This article was edited by Mark Staples, an executive editor in the New York office.

We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

September 21, 2020

Normalcy by spring, and herd immunity by fall? We assess the prospects for an end in 2021.

In 1920, a world wearied by the First World War and sickened by the 1918 flu pandemic desperately sought to move past the struggles and tragedies and start to rebuild lives. People were in search of a “return to normalcy,” as Warren G. Harding put it. Today, nearly every country finds itself in a similar position.

More than eight months and 900,000 deaths into the COVID-19 pandemic, 119 119. Coronavirus Resource Center, Johns Hopkins University & Medicine, September 18, 2020, daypg.com. people around the world are longing for an end. In our view, there are two important definitions of “end,” each with a separate timeline:

• An epidemiological end point when herd immunity is achieved. One end point will occur when the proportion of society immune to COVID-19 is sufficient to prevent widespread, ongoing transmission. Many countries are hoping that a vaccine will do the bulk of the work needed to achieve herd immunity. When this end point is reached, the public-health-emergency interventions deployed in 2020 will no longer be needed. While regular revaccinations may be needed, perhaps similar to annual flu shots, the threat of widespread transmission will be gone.
• A transition to a form of normalcy. A second (and likely, earlier) end point will occur when almost all aspects of social and economic life can resume without fear of ongoing mortality (when a mortality rate is no longer higher than a country’s historical average) or long-term health consequences related to COVID-19. The process will be enabled by tools such as vaccination of the highest-risk populations; rapid, accurate testing; improved therapeutics; and continued strengthening of public-health responses. The next normal won’t look exactly like the old—it might be different in surprising ways, with unexpected contours, and getting there will be gradual—but the transition will enable many familiar scenes, such as air travel, bustling shops, humming factories, full restaurants, and gyms operating at capacity, to resume.

The two ends are related, of course, but not linearly. At the latest, the transition to normal will come when herd immunity is reached. But in regions with strong public-health responses, normalcy can likely come significantly before the epidemiological end of the pandemic.

The timeline to achieve the ends will vary by location. In this article, we’ll explain the criteria that will be key factors in determining when each is reached. In the United States and most other developed economies, the epidemiological end point is most likely to be achieved in the third or fourth quarter of 2021, with the potential to transition to normalcy sooner, possibly in the first or second quarter of 2021. Every day matters. Beyond the impatience that most feel to resume normal life, the longer it takes to remove the constraints on our economies, the greater will be the economic damage.

The epidemiological end point

Most countries have deferred the hope of achieving herd immunity until the arrival of a vaccine. When herd immunity is reached, ongoing public-health interventions for COVID-19 can stop without fear of resurgence. The timing of the end point will vary by country and will be affected by a number of factors:

• the arrival, efficacy, and adoption of COVID-19 vaccines—the biggest drivers in the timeline to herd immunity 120 120. Virus-neutralizing antibodies could also confer immunity but are less likely to be deployed at sufficient scale to achieve herd immunity in large populations.
• the level of natural immunity in a population from exposure to COVID-19; in our estimate, between 90 million and 300 million people globally may have natural immunity 121 121. For calculation and sources, see sidebar, “Key factors affecting the timeline to herd immunity.”
• potential cross-immunity from exposure to other coronaviruses 122 122. Jose Mateus et al., “Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans,” Science, August 4, 2020, daypg.com.
• potential partial immunity conferred by other immunizations, such as the bacille Calmette-Guérin (BCG) vaccine for tuberculosis 123 123. Martha K. Berg et al., “Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19,” Science Advances, August 2020, Volume 6, Number 32, daypg.com.
• regional differences in the ways that people mix, which will produce different thresholds for herd immunity

Consider the first and most crucial variables: the arrival of vaccines, their efficacy, and their adoption. We see four plausible scenarios for vaccine efficacy and adoption, illustrated in Exhibit 1. 124 124. Exhibit 1 assumes a basic reproductive number (R0) of 2.4 and uses a standard formula to arrive at an estimated herd-immunity threshold of 58 percent. Different combinations of those two factors will drive varying levels of conferred immunity, implying the extent of natural immunity that will be required to reach herd immunity under each scenario. Combinations of efficacy and adoption beyond those shown are possible.

Exhibit 1 We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@daypg.com

The other variables will also have much to say about the timeline to reach herd immunity (see sidebar, “Key factors affecting the timeline to herd immunity”).

Based on our reading of the current state of the variables and their likely progress in the coming months, we estimate that the most likely time for the United States to achieve herd immunity is the third or fourth quarter of 2021. As we wrote in July 2020, one or more vaccines may receive US Food and Drug Administration Emergency Use Authorization before the end of 2020 (or early in 2021) and the granting of a Biologics License Application (also known as approval) during the first quarter of 2021.

Vaccine distribution to a sufficient portion of a population to induce herd immunity could take place in as few as six months. That will call for rapid availability of hundreds of millions of doses, functioning vaccine supply chains, and peoples’ willingness to be vaccinated during the first half of 2021. We believe that those are all reasonable expectations, based on public statements from vaccine manufacturers and the results of surveys on consumer sentiment about vaccines. 125 125. Joe Myers, “3 in 4 adults around the world say they would get a COVID-19 vaccine,” World Economic Forum, September 1, 2020, daypg.com.

Herd immunity could be reached as soon as the second quarter of 2021 if vaccines are highly effective and launched smoothly or if significant cross-immunity is discovered in a population (Exhibit 2). (For more on the potential for a faster resolution of the COVID-19 crisis in the United States, see “An optimistic scenario for the US response to COVID-19”.) On the other hand, the epidemiological end of the pandemic might not be reached until 2022 or later if the early vaccine candidates have efficacy or safety issues—or if their distribution and adoption are slow. At worst, we see a long-tail possibility that the United States could be still battling COVID-19 into 2023 and beyond if a constellation of factors (such as low efficacy of vaccines and a short duration of natural immunity) align against us.

The paths to herd immunity in other high-income countries are likely to be broadly similar to the one in the United States. The timelines will vary based on differences in vaccine access and rollout and in levels of natural immunity—and potentially, in levels of cross-immunity and previous coverage of other vaccines, such as the BCG vaccine. Even as some locations reach herd immunity, pockets of endemic COVID-19 disease are likely to remain around the world, for example in areas affected by war or in communities with persistently low adoption of vaccines. In such places, until herd immunity is reached, COVID-19 might be analogous to measles—not a day-to-day threat to most people, but a persistent risk. If immunity wanes—for example, if booster vaccines are not fully adopted—then COVID-19 could become more widely endemic.

The arrival of herd immunity won’t mean a complete end to all public-health interventions. It’s possible that regular revaccinations would be required to maintain immunity, and ongoing surveillance for COVID-19 will be required. But herd immunity would mean that the emergency measures currently in place in many countries could be lifted.

The pace at which governments relax public-health measures will be critical. Some of those measures (such as full lockdowns and restrictions on certain industries) have significant social and economic consequences, and others (such as testing and tracing), while expensive, don’t. Many governments are employing packages of measures that aim to minimize the number of COVID-19 cases and excess mortality while maximizing social and economic degrees of freedom.

The transition to normal

The second end point of the pandemic may be reached earlier than the first. We estimate that the mostly likely time for this to occur is the first or second quarter of 2021 in the United States and other advanced economies. The key factor is diminished mortality.

Society has grown used to tracking the number of COVID-19 infections (the case count). But case counts matter primarily because people are dying from the disease and because those who survive it may suffer long-term health consequences after infection. The latter is an area of scientific uncertainty, but there is concern that some recovered patients will face long-term effects. 126 126. “COVID-19 (coronavirus): Long-term effects,” Mayo Clinic, August 18, 2020, daypg.com.

Most countries have made significant progress in reducing the numbers of deaths and hospitalizations associated with COVID-19. Some are close to eliminating excess mortality. Those results have generally been achieved through a combination of moderately effective interventions rather than a single “big bang” (Exhibit 3).

A transition to the next normal, in whatever form that takes, will come gradually when people have confidence that they can do what they used to do without endangering themselves or others. Gaining that confidence will require a continuation of the progress made to reduce mortality and complications, as well as further scientific study regarding long-term health consequences for recovered patients. When confidence is restored, people will again fill bars, restaurants, theaters, and sports venues to full capacity; fly overseas (except for the highest-risk populations); and receive routine medical care at levels similar to those seen prior to the pandemic.

The timing of such a transition will depend on the progress toward herd immunity, as previously detailed (since more people with immunity means fewer deaths and long-term health consequences), and on the effectiveness of a country’s public-health response. Transitions will be gradual. They have already begun in some locations and could be well advanced in most countries by the first or second quarter of 2021. Given the interconnectedness of the global economy, country timelines to normalcy are not fully independent of one another.

To achieve that, we will need to see significant progress on the epidemiological end point, including an effective vaccine receiving Emergency Use Authorization approval during the fourth quarter of 2020 or the first quarter of 2021, followed by a smooth rollout and adoption by high-risk populations. Favorable findings on natural and cross-immunity would help accelerate timelines. Five additional criteria will also contribute to the transition to a form of normalcy—the more of these that are achieved, the faster the milestone is likely to be reached:

• continued improvement by governments in the application of public-health interventions (such as test and trace) that don’t significantly limit economic and social activities
• compliance with public-health measures until we achieve herd immunity
• accurate, widely available, rapid testing that effectively enables specific activities
• continued advancements in therapeutics (including pre- and postexposure prophylactics) for and clinical management of COVID-19, leading to lower infection-fatality ratios—substantial progress has already been made through a combination of effective drugs, such as dexamethasone and remdesivir, and changes in clinical management
• public confidence that there aren’t significant long-term health consequences for those who recover from COVID-19

Both the epidemiological and normalcy ends to the COVID-19 pandemic are important. The transition to the next normal will mark an important social and economic milestone, and herd immunity will be a more definitive end to the pandemic. In the United States, while the transition to normal might be accomplished sooner, the epidemiological end point looks most likely to be reached in the second half of 2021. Other advanced economies are probably on similar timetables.

Download the article here.